Drug

Dalteparin

In clinical development

ClassAntithrombin-III activatorEmerging researchLate-stage developmentRising momentum

Also known as Fragmin, dalteparin,porcine, Daltéparine.

RxNorm67109 ChEMBLCHEMBL1201460 ATCB01AB04UNIIS79O08V79F

Research papers

Active clinical trials

Antithrombin-III

Primary target

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab vs. Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients With GI/GU Associated VTE

Clinical trial2026-04-10Terminated · ClinicalTrials.gov

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

Clinical trial2025-12-17Results expected Q4 2026 · ClinicalTrials.gov

A Multi-centre Randomised Adaptive Platform Clinical Trial to Assess Clinical, Virological and Immunological Outcomes in Patients With SARS-CoV-2 Infection (COVID-19)

Clinical trial2025-07-25Primary completion · ClinicalTrials.gov

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

Clinical trial2025-06-24Results posted · ClinicalTrials.gov

PROTEST Trial - PROphylaxis for Venous ThromboEmbolism in Severe Traumatic Brain Injury, a Double-blind Randomized Controlled Trial

Clinical trial2024-09-19Results expected Q4 2026 · ClinicalTrials.gov

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

Clinical trial2024-05-01Completed · ClinicalTrials.gov

FRAG-A001-401: Dalteparin Sodium Injection (Fragmin), Multicenter, Open-Label, Single-arm, Long Term (52 Weeks) Study for Understanding the Safety and Efficacy in Subjects With Malignancies and Symptomatic Venous Thromboembolism

Clinical trial2024-04-18Results posted · ClinicalTrials.gov

A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism

Clinical trial2023-11-30Terminated · ClinicalTrials.gov

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

Clinical trial2023-10-03Results posted · ClinicalTrials.gov

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

Research2020-03-29The New England journal of medicine

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

Research2017-12-12The New England journal of medicine

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

Research2003-07-01The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Dalteparin

Aliases & brands

Fragmindalteparin,porcineDaltéparine

RxNorm CUI

67109

ChEMBL ID

CHEMBL1201460

ATC codes

B01AB04

UNII

S79O08V79F

Primary mechanism

Antithrombin-III activator

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Antithrombin-III

SERPINC1 · P01008

ACTIVATORAntithrombin-III activator

Clinical trials

41 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2024

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 41

Phase 11Phase 1 / 21Phase 211Phase 314Phase 410Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

RecruitingPH IVTzu-Fei Wangn=502027

Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses

CompletedPH IVKey trialAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)n=1,1102021

A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients: A Prospective Study

CompletedPH IVLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sn=152018

Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial

CompletedPH IVThomas Decker Christensenn=1162015

Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.

CompletedPH IVM.D. Anderson Cancer Centern=872014

Recent completions

Trials that read out recently, adding to the completed evidence base.

Causes and Prevention of Thromboembolic Disease in Nephrotic Syndrome

CompletedPH I/IIUniversity of Aarhusn=572024

Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses

CompletedPH IVKey trialAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)n=1,1102021

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)

CompletedN/AAlliance Foundation Trials, LLC.n=8112021

DVT Prophylaxis in Orthopaedic Oncology Patients - A Safety Study

CompletedN/AM.D. Anderson Cancer Centern=652020

A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism

CompletedPH IIIAcademic and Community Cancer Research Unitedn=3002019

Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study

CompletedPH IIIKey trialFadoi Foundation, Italyn=1,1702019

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20032020

Most influential

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.

The New England journal of medicine · 2003 · 1,599 cites

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.

The New England journal of medicine · 2018 · 1,036 cites

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.

The New England journal of medicine · 2020 · 671 cites

Related diseases

5 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Hemorrhage3 Neoplasms3 Pulmonary Embolism2 Venous Thromboembolism2 Venous Thrombosis2

Related drugs

4 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Acenocoumarol

Studied across 5 of the same disease areas as Dalteparin in the shared literature.

5 shared diseases1 shared paper

Apixaban

Studied across 5 of the same disease areas as Dalteparin in the shared literature.

5 shared diseases1 shared paper

Warfarin

Studied across 5 of the same disease areas as Dalteparin in the shared literature.

5 shared diseases1 shared paper

Edoxaban

Studied across 3 of the same disease areas as Dalteparin in the shared literature.

3 shared diseases1 shared paper

References & data sources

RxNorm (U.S. National Library of Medicine) — drug identity
ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
Europe PMC — research literature
ClinicalTrials.gov — clinical trials